Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Apogee Therapeutics, Inc.NASDAQ: APGE
Total Assets · Q2 FY2026 · quarter ended Jun 2026
Total assets rises 103.1% from a year ago
Total assets stood at $1.34B at the end of Q2 FY2026, up 103.1% from a year earlier and up 3.3% from the prior quarter. Over 3 fiscal years it compounded at +83.3% a year.
Context
- Total assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +103.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 937.13M USD
- Year-over-year change
- +24.3%
- 3-year CAGR
- +83.3%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 937.13M | +24.3% |
| FY2024 | 2024-12-31 | 753.95M | +87.8% |
| FY2023 | 2023-12-31 | 401.4M | +164.0% |
| FY2022 | 2022-12-31 | 152.06M | — |
Total Assets vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of +103.1% is the 2nd highest of 10, against a peer median of +21.6%.
- Over three fiscal years its annual growth of +83.3% compares with a peer median of +11.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥3.97B CNY | +51.5% | +11.9% |
| Sep 2026 | $1.68B USD | -1.8% | +9.2% | |
| Jun 2026 | $1.34B USD | +103.1% | +83.3% | |
| Mar 2026 | $1.3B USD | -1.2% | -0.3% | |
| Sep 2026 | $1.2B USD | +97.4% | +9.2% | |
| Jun 2026 | $1.07B USD | -7.7% | -1.3% | |
| Sep 2026 | $1.05B USD | +43.4% | +75.0% | |
| Jun 2026 | $828.22M USD | +351.1% | +38.5% | |
IRONDisc Medicine, Inc. | Sep 2026 | $699.49M USD | +10.9% | +59.1% |
| Mar 2026 | $641.76M USD | +21.6% | +15.7% | |
| Peer median (excluding APGE) | — | +21.6% | +11.9% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.